TG Therapeutics completes enrollment for subcutaneous BRIUMVI trial

April 15, 2026 7:30 AM

TG Therapeutics Inc. (NASDAQ: TGTX) announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI for relapsing ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found